Healthcare provider profile · identity verified

Bryan Parmer, DO

Family Practice · ST PETERSBURG, FL · NPI 1558334789

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	372	127
Atorvastatin Calcium	Atorvastatin Calcium	333	122
Amlodipine Besylate	Amlodipine Besylate	326	113
Rosuvastatin Calcium	Rosuvastatin Calcium	285	106
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	244	44
Metoprolol Succinate	Metoprolol Succinate	226	86
Lisinopril	Lisinopril	225	84
Meloxicam	Meloxicam	199	78
Tramadol Hcl	Tramadol Hcl	172	46
Levothyroxine Sodium	Levothyroxine Sodium	168	56
Baclofen	Baclofen	147	61
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	147	22
Methylprednisolone	Methylprednisolone	143	119
Alprazolam	Alprazolam	134	29
Glipizide Er	Glipizide	129	46
Metformin Hcl	Metformin Hcl	129	43
Tamsulosin Hcl	Tamsulosin Hcl	125	47
Pantoprazole Sodium	Pantoprazole Sodium	121	54
Omeprazole	Omeprazole	111	38
Gabapentin	Gabapentin	100	43
Temazepam	Temazepam	95	18
Trazodone Hcl	Trazodone Hcl	94	32
Escitalopram Oxalate	Escitalopram Oxalate	91	38
Albuterol Sulfate Hfa	Albuterol Sulfate	90	34
Metoprolol Tartrate	Metoprolol Tartrate	89	28
Alendronate Sodium	Alendronate Sodium	88	30
Famotidine	Famotidine	84	36
Hydrochlorothiazide	Hydrochlorothiazide	79	27
Eliquis	Apixaban	68	21
Duloxetine Hcl	Duloxetine Hcl	65	28
Hydralazine Hcl	Hydralazine Hcl	62	16
Azithromycin	Azithromycin	59	54
Potassium Chloride	Potassium Chloride	57	24
Fenofibrate	Fenofibrate	56	21
Montelukast Sodium	Montelukast Sodium	56	28
Furosemide	Furosemide	54	24
Levofloxacin	Levofloxacin	52	45
Donepezil Hcl	Donepezil Hcl	50	17
Clopidogrel	Clopidogrel Bisulfate	48	17
Fluticasone Propionate	Fluticasone Propionate	44	27
Sildenafil Citrate	Sildenafil Citrate	42	12
Pioglitazone Hcl	Pioglitazone Hcl	38	11
Warfarin Sodium	Warfarin Sodium	36	suppressed
Simvastatin	Simvastatin	35	15
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	34	suppressed
Spironolactone	Spironolactone	33	12
Atenolol	Atenolol	32	12
Celecoxib	Celecoxib	32	11
Sertraline Hcl	Sertraline Hcl	32	11
Triamcinolone Acetonide	Triamcinolone Acetonide	32	21
Jardiance	Empagliflozin	31	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	11
Cephalexin	Cephalexin	29	20
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	29	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	27
Finasteride	Finasteride	28	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	25
Januvia	Sitagliptin Phosphate	26	suppressed
Risperidone	Risperidone	26	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	26	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Carvedilol	Carvedilol	25	11
Carisoprodol	Carisoprodol	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Valsartan	Valsartan	23	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	22	suppressed
Allopurinol	Allopurinol	22	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Diazepam	Diazepam	22	suppressed
Ibuprofen	Ibuprofen	22	suppressed
Ondansetron Odt	Ondansetron	22	14
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Mirtazapine	Mirtazapine	21	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	15
Doxycycline Hyclate	Doxycycline Hyclate	19	18
Ezetimibe	Ezetimibe	19	suppressed
Raloxifene Hcl	Raloxifene Hcl	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Morphine Sulfate Er	Morphine Sulfate	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Methotrexate	Methotrexate Sodium	16	suppressed
Mometasone Furoate	Mometasone Furoate	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Amiodarone Hcl	Amiodarone Hcl	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Cholestyramine	Cholestyramine (With Sugar)	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	13
Valacyclovir	Valacyclovir Hcl	14	suppressed
Cimetidine	Cimetidine	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Novolin R	Insulin Regular, Human	12	suppressed
Novolin R Flexpen	Insulin Regular, Human	12	suppressed
Amoxicillin	Amoxicillin	11	11
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error